These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24055507)

  • 1. Bioreducible hyaluronic acid conjugates as siRNA carrier for tumor targeting.
    Yoon HY; Kim HR; Saravanakumar G; Heo R; Chae SY; Um W; Kim K; Kwon IC; Lee JY; Lee DS; Park JC; Park JH
    J Control Release; 2013 Dec; 172(3):653-61. PubMed ID: 24055507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors.
    Son S; Song S; Lee SJ; Min S; Kim SA; Yhee JY; Huh MS; Chan Kwon I; Jeong SY; Byun Y; Kim SH; Kim K
    Biomaterials; 2013 Dec; 34(37):9475-85. PubMed ID: 24050874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-specific delivery of siRNA using supramolecular assembly of hyaluronic acid nanoparticles and 2b RNA-binding protein/siRNA complexes.
    Choi KM; Jang M; Kim JH; Ahn HJ
    Biomaterials; 2014 Aug; 35(25):7121-32. PubMed ID: 24854094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gold-installed biostable nanocomplexes for tumor-targeted siRNA delivery in vivo.
    Heo R; Yoon HY; Ko H; Shin JM; Jeon J; Chae YS; Kang YM; Kim D; Lee DS; Park JH
    Chem Commun (Camb); 2015 Dec; 51(93):16656-9. PubMed ID: 26426483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery.
    Shen Y; Wang B; Lu Y; Ouahab A; Li Q; Tu J
    Int J Pharm; 2011 Jul; 414(1-2):233-43. PubMed ID: 21545832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid complexed to biodegradable poly L-arginine for targeted delivery of siRNAs.
    Kim EJ; Shim G; Kim K; Kwon IC; Oh YK; Shim CK
    J Gene Med; 2009 Sep; 11(9):791-803. PubMed ID: 19569085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo.
    Choi KM; Kim K; Kwon IC; Kim IS; Ahn HJ
    Mol Pharm; 2013 Jan; 10(1):18-25. PubMed ID: 22663765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance.
    Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Huang K; Chen X; Zhang Z; He Q
    Int J Pharm; 2014 Dec; 477(1-2):590-600. PubMed ID: 25448564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient intracellular siRNA delivery strategy through rapid and simple two steps mixing involving noncovalent post-PEGylation.
    Kong WH; Sung DK; Shim YH; Bae KH; Dubois P; Park TG; Kim JH; Seo SW
    J Control Release; 2009 Sep; 138(2):141-7. PubMed ID: 19426771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate.
    Park K; Lee MY; Kim KS; Hahn SK
    Biomaterials; 2010 Jul; 31(19):5258-65. PubMed ID: 20378167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery.
    Tanaka K; Kanazawa T; Horiuchi S; Ando T; Sugawara K; Takashima Y; Seta Y; Okada H
    Int J Pharm; 2013 Oct; 455(1-2):40-7. PubMed ID: 23911914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
    Zhang L; Yao J; Zhou J; Wang T; Zhang Q
    Int J Pharm; 2013 Jan; 441(1-2):654-64. PubMed ID: 23117024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.
    Alshamsan A; Hamdy S; Samuel J; El-Kadi AO; Lavasanifar A; Uludağ H
    Biomaterials; 2010 Feb; 31(6):1420-8. PubMed ID: 19913908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
    Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
    Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery.
    Han HS; Thambi T; Choi KY; Son S; Ko H; Lee MC; Jo DG; Chae YS; Kang YM; Lee JY; Park JH
    Biomacromolecules; 2015 Feb; 16(2):447-56. PubMed ID: 25565417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioreducible polyethylenimine-delivered siRNA targeting human telomerase reverse transcriptase inhibits HepG2 cell growth in vitro and in vivo.
    Xia W; Wang P; Lin C; Li Z; Gao X; Wang G; Zhao X
    J Control Release; 2012 Feb; 157(3):427-36. PubMed ID: 22036880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural contributions of blocked or grafted poly(2-dimethylaminoethyl methacrylate) on PEGylated polycaprolactone nanoparticles in siRNA delivery.
    Lin D; Huang Y; Jiang Q; Zhang W; Yue X; Guo S; Xiao P; Du Q; Xing J; Deng L; Liang Z; Dong A
    Biomaterials; 2011 Nov; 32(33):8730-42. PubMed ID: 21885115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate.
    Lee MS; Lee JE; Byun E; Kim NW; Lee K; Lee H; Sim SJ; Lee DS; Jeong JH
    J Control Release; 2014 Oct; 192():122-30. PubMed ID: 24995950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-targeting transferrin nanoparticles for systemic polymerized siRNA delivery in tumor-bearing mice.
    Yhee JY; Lee SJ; Lee S; Song S; Min HS; Kang SW; Son S; Jeong SY; Kwon IC; Kim SH; Kim K
    Bioconjug Chem; 2013 Nov; 24(11):1850-60. PubMed ID: 24107100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA.
    Cho WY; Hong SH; Singh B; Islam MA; Lee S; Lee AY; Gankhuyag N; Kim JE; Yu KN; Kim KH; Park YC; Cho CS; Cho MH
    Eur J Pharm Biopharm; 2015 Aug; 94():450-62. PubMed ID: 26141346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.